同益股份(300538.SZ):參股公司聚賽龍IPO獲證監會同意註冊批覆
格隆匯2月10日丨同益股份(300538.SZ)公佈,根據中國證監會於2022年2月8日發佈的《關於同意廣州市聚賽龍工程塑料股份有限公司首次公開發行股票註冊的批覆》,同意聚賽龍首次公開發行股票的註冊申請,批覆自同意註冊之日起12個月內有效。聚賽龍將根據中國證監會及深圳證券交易所相關規定及要求開展後續工作。
截至公吿披露日,公司持有聚賽龍166.5125萬股股份,佔其發行前股份總數的4.65%,該部分股份自聚賽龍上市之日起12個月內不得轉讓。目前聚賽龍股份發行價格尚未確定,對公司未來財務狀況和經營成果的影響暫無法確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.